{"id":155605,"date":"2025-10-31T16:33:07","date_gmt":"2025-10-31T16:33:07","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/155605\/"},"modified":"2025-10-31T16:33:07","modified_gmt":"2025-10-31T16:33:07","slug":"immune-cells-key-to-boosting-cancer-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/155605\/","title":{"rendered":"Immune Cells Key To Boosting Cancer Immunotherapy"},"content":{"rendered":"

Mayo Clinic<\/a>\u00a0researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using distinct approaches, found that “first-responder” immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.<\/p>\n

The finding suggests that enhanced myeloid cells may boost certain immune checkpoint therapies, which are the standard of care for some cancers but may not have lasting effects. A clinical trial is now being developed at Mayo Clinic to test the enhanced cells in patients.<\/p>\n

In a study in\u00a0Journal for ImmunoTherapy of Cancer<\/a>, Mayo Clinic researchers detailed how they found a way to boost cancer-killing T cells. The goal was to improve treatments that interfere with immunosuppressive proteins, PD-1 and PD-L1, which together suppress T cells’ ability to fight cancer. Even though PD-L1 immunotherapies aim to block PD-L1, the researchers found that the molecule can persist through a natural recycling process that puts it back in play.<\/p>\n

“Our study found the importance of the recycling process, and we present a way to address it,” says\u00a0Haidong Dong, M.D., Ph.D.<\/a>, a cancer immunology researcher at\u00a0Mayo Clinic Comprehensive Cancer Center<\/a>\u00a0and principal investigator of the study.<\/p>\n

The research team developed an antibody, H1A, which they found can reduce PD-L1 in human myeloid cells and keep it from recycling. The protein PD-L1 is present in abundance on the surface of myeloid cells. When the protein was prevented from recycling on myeloid cells, the cells then boosted the action of cancer-killing T cells.<\/p>\n

“We now have a tool that can completely remove PD-L1 and in doing so we have more myeloid cell activation,” says lead author of the study, Michelle Hsu, who conducted the research as her graduate thesis at\u00a0Mayo Clinic Graduate School of Biomedical Sciences<\/a>. “Identifying the myeloid cell was an unexpected discovery,” she says.<\/p>\n

Another Mayo Clinic team took a different approach and arrived at a similar conclusion about the importance of myeloid cells. A research team led by immunology researcher\u00a0Jessica Lancaster, Ph.D.<\/a>, at\u00a0Mayo Clinic in Arizona<\/a>, reported in\u00a0iScience<\/a>\u00a0that macrophages, a type of myeloid cell, play a role in activating the cancer-killing T cells.<\/p>\n

Using the complex approach of live-cell microscopy, the team found that in mice, T cells interact closely with the macrophages and create a molecular environment that has greater capacity to kill a tumor.<\/p>\n

“This is a paradigm shift for PD-L1 immunotherapy, which has traditionally focused on the interaction of the tumor and the T cells,” says Dr. Lancaster. “We found that it\u2019s important to co-opt the macrophage, which acts as another immune cell partner.”<\/p>\n

Further, says lead author Tina Kwok, who completed the studies during her Ph.D. research at Mayo Clinic, “We can directly reprogram tumor macrophages to be more pro-inflammatory. They can become better T-cell activators and drive better tumor control. Reprogramming of the macrophage may be key to being able to prevent therapy resistance and change outcomes for patients.”<\/p>\n

Based on the findings from both labs, a phase 1 clinical trial of H1A is being planned. The research could ultimately better address resistance to immunotherapy and expand treatment options for people with cancer.<\/p>\n

References:\u00a0<\/b><\/p>\n


<\/b>1. Hsu MA, Liu X, Barham W, et al. Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion. J Immunother Cancer. 2025;13(10). doi:\u00a010.1136\/jitc-2025-012164<\/a><\/p>\n

2.\u00a0Kwok T, Silva-Junior IA, Korpe S, Dong H, Lancaster JN. Macrophage repolarization by immune checkpoint blockade drives T cell engagement in the tumor microenvironment. iScience. 2025;28(10):113538. doi:\u00a010.1016\/j.isci.2025.113538<\/a><\/p>\n

This article has been republished from the following materials<\/a>. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Mayo Clinic\u00a0researchers have identified a specific immune cell that can be targeted to give a boost to standard…\n","protected":false},"author":2,"featured_media":155606,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[74],"tags":[18,19,17,82],"class_list":{"0":"post-155605","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-technology","8":"tag-eire","9":"tag-ie","10":"tag-ireland","11":"tag-technology"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115469746492716773","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/155605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=155605"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/155605\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/155606"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=155605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=155605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=155605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}